{"title":"The Effect of Black Seed Oil as Adjuvant Therapy on Nuclear Factor Erythroid 2-Related Factor 2 Levels in Patients with Metabolic Syndrome Risk","authors":"R. A. H. Wahid, E. Darmawan","doi":"10.22034/IJPS.2019.94568.1484","DOIUrl":null,"url":null,"abstract":"Nuclear factor erythroid 2-related factor 2 (Nrf2) is one of the transcription factors involved in providing endogenous antioxidants. Black seed oil (BSO), suspected have antioxidant effects that can be used to modulate the expression and levels of Nrf2. The study aims to determine the effect of BSO as adjuvant therapy on levels of Nrf2 to the patients with metabolic syndrome risk. The research used analytical observational with cohort design. Samples study consisted of 62 patients at risk with metabolic syndrome risk at Jetis I Public Health Center, Bantul District, from September to December 2016. Eligible subjects were divided into two groups, (1) BSO group, patients get BSO with a dose of 3 mL/day and standard therapy for 20 days. (2) Control group, patients got placebo and standard therapy during the intervention for 20 days. Level of Nrf2 were estimates using enzyme-linked immunosorbent assay (ELISA) method. The mean values ± SD between groups were tested with independent t-test with significance of p= The results showed that Nrf2 in group 1 was 0,866 ± 0,11 ng/ml and the group 2 was 0,864 ± 0,15 ng/mL (p=0,94). There were no significant difference in the both groups (p>0.05). In conclusion, adjuvant therapy of BSO doses 3 mL/day for 20 days could not increase levels of Nrf2 in the patients with metabolic syndrome risk based on type treatment and demographic characteristic at Jetis I Public Health Center, Bantul District.","PeriodicalId":14582,"journal":{"name":"Iranian Journal of Pharmaceutical Sciences","volume":"16 1","pages":"9-18"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22034/IJPS.2019.94568.1484","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 4
Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) is one of the transcription factors involved in providing endogenous antioxidants. Black seed oil (BSO), suspected have antioxidant effects that can be used to modulate the expression and levels of Nrf2. The study aims to determine the effect of BSO as adjuvant therapy on levels of Nrf2 to the patients with metabolic syndrome risk. The research used analytical observational with cohort design. Samples study consisted of 62 patients at risk with metabolic syndrome risk at Jetis I Public Health Center, Bantul District, from September to December 2016. Eligible subjects were divided into two groups, (1) BSO group, patients get BSO with a dose of 3 mL/day and standard therapy for 20 days. (2) Control group, patients got placebo and standard therapy during the intervention for 20 days. Level of Nrf2 were estimates using enzyme-linked immunosorbent assay (ELISA) method. The mean values ± SD between groups were tested with independent t-test with significance of p= The results showed that Nrf2 in group 1 was 0,866 ± 0,11 ng/ml and the group 2 was 0,864 ± 0,15 ng/mL (p=0,94). There were no significant difference in the both groups (p>0.05). In conclusion, adjuvant therapy of BSO doses 3 mL/day for 20 days could not increase levels of Nrf2 in the patients with metabolic syndrome risk based on type treatment and demographic characteristic at Jetis I Public Health Center, Bantul District.
期刊介绍:
Iranian Journal of Pharmaceutical Sciences (IJPS) is an open access, internationally peer-reviewed journal that seeks to publish research articles in different pharmaceutical sciences subdivisions: pharmacology and toxicology, nanotechnology, pharmaceutics, natural products, biotechnology, pharmaceutical chemistry, clinical pharmacy and other pharmacy related topics. Each issue of the journal contents 16 outstanding research articles in area of pharmaceutical sciences plus an editorial written by the IJPS editors on one of the most up to date advances topics in pharmacy. All articles published by IJPS would be permanently accessible online freely without any subscription charges. Authors of the published articles have granted the right to use and disseminate their article to third parties.